双岐杆菌活菌制剂对肝硬化患者内毒素血症的治疗作用

Therapeutic Effect of Viable Bifidobacteria on Endotoxemia in Patients with Hepatic Cirrhosis

用双盲给药法观察双歧杆菌活菌制剂口服治疗20例肝硬化内毒素血症的效果.结果显示该制剂有明显降低内毒素血症的作用.有效率在治疗组和对照组分别为73.33%和15.38%,P<0.005.两种不同机制产生的内毒素血症动物模型在该制剂灌胃后鲎试验阴转数为3/5只.粪便菌群计数肠杆菌数量较治疗前减少,双歧杆菌数增加,提示双歧杆菌活菌制剂治疗机制可能通过抑制肠道革兰氏阴性杆菌生长,减少了内毒素的产生.

The therapeutic effect of viable bifidobacteria on endotoxemia was studied in 20 patients with hepatic cirrhosis by double-blind oral administration. The results showed that viable bifidobacteria was able to improve endotoxemia effectively. The effective rate in the therapeutic group and controls was 73.33% and 15.38%, re-spectively. After bifidobacteria was administered intragastrically to two animal mod-els with endotoxemia produced by two different agents, the number of the animal be-coming negative in LLT was 3/5, and the bacterial colony count in stool and the in-testinal bacteria were decreased after treatment, but bifidobacteria were increased. This suggests that the therapeutic mechanism may be related to the inhibition of in-testinal gram-negative bacteria, decreasing the production of endtoxemia.